| 1 |
33256506 | Effects of breviscapine and C3435T MDR1 gene polymorphism on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. | 2021 Mar |
4 |
| 2 |
33825113 | Chiral Transplacental Pharmacokinetics of Fexofenadine: Impact of P-Glycoprotein Inhibitor Fluoxetine Using the Human Placental Perfusion Model. | 2021 Apr |
3 |
| 3 |
33832418 | The Role of P-Glycoprotein in Decreasing Cell Membranes Permeability during Oxidative Stress. | 2021 Feb |
1 |
| 4 |
32557079 | Chiral Discrimination of P-glycoprotein in Parturient Women: Effect of Fluoxetine on Maternal-Fetal Fexofenadine Pharmacokinetics. | 2020 Jun 17 |
2 |
| 5 |
33372901 | [Evaluation of female sex hormones influence on the protein-transporter p-glycoprotein functioning in vitro]. | 2020 Nov |
1 |
| 6 |
30280663 | Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism. | 2019 |
5 |
| 7 |
31581637 | Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail. | 2019 Oct 2 |
1 |
| 8 |
29635947 | An update on the clinical pharmacokinetics of fexofenadine enantiomers. | 2018 Apr |
2 |
| 9 |
30020547 | Impact of ABCB1 genotype in Collies on the pharmacokinetics of R- and S-fexofenadine. | 2018 Dec |
1 |
| 10 |
27981349 | The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers. | 2017 Mar |
3 |
| 11 |
28090646 | Influence of P-glycoprotein on the disposition of fexofenadine and its enantiomers. | 2017 Mar |
8 |
| 12 |
28301431 | CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease. | 2017 May |
1 |
| 13 |
26467209 | Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites. | 2016 |
1 |
| 14 |
25263393 | Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers. | 2015 Feb |
1 |
| 15 |
25759055 | [Determinants of the stereoselective pharmacokinetics of fexofenadine]. | 2015 |
4 |
| 16 |
25908246 | Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration. | 2015 Jul |
1 |
| 17 |
25953731 | Design of Fexofenadine Prodrugs Based on Tissue-Specific Esterase Activity and Their Dissimilar Recognition by P-Glycoprotein. | 2015 Sep |
1 |
| 18 |
24423593 | Simultaneous LC-MS/MS quantification of P-glycoprotein and cytochrome P450 probe substrates and their metabolites in DBS and plasma. | 2014 Jan |
1 |
| 19 |
23115085 | Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. | 2013 Jan |
1 |
| 20 |
23422332 | Investigation on modulation of human P-gp by multiple doses of Radix Astragali extract granules using fexofenadine as a phenotyping probe. | 2013 Apr 19 |
2 |
| 21 |
24040855 | The role of multidrug resistance-1 (MDR1) variants in response to fexofenadine among Jordanians. | 2013 Nov |
5 |
| 22 |
21646440 | Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. | 2012 Jun |
1 |
| 23 |
21950458 | Carbamazepine differentially affects the pharmacokinetics of fexofenadine enantiomers. | 2012 Mar |
3 |
| 24 |
22198458 | Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters? | 2012 Feb |
1 |
| 25 |
19947891 | Clinical pharmacokinetics of fexofenadine enantiomers. | 2010 Jan |
5 |
| 26 |
20214407 | Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. | 2010 Apr |
1 |
| 27 |
20306185 | Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers. | 2010 Jul |
2 |
| 28 |
20839930 | Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. | 2010 Nov |
2 |
| 29 |
21039758 | Fruit juice inhibition of uptake transport: a new type of food-drug interaction. | 2010 Nov |
1 |
| 30 |
19204737 | Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG. | 2009 Jun |
3 |
| 31 |
19221726 | Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. | 2009 Jun |
2 |
| 32 |
19552748 | Enantioselective disposition of fexofenadine with the P-glycoprotein inhibitor verapamil. | 2009 May |
10 |
| 33 |
18294330 | The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. | 2008 May |
6 |
| 34 |
18511651 | Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine. | 2008 Aug |
1 |
| 35 |
18570599 | The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers. | 2008 Jul |
2 |
| 36 |
19238656 | Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. | 2008 Oct |
1 |
| 37 |
17230498 | Pharmacokinetics of fexofenadine enantiomers in healthy subjects. | 2007 Mar |
4 |
| 38 |
16964701 | [Is MDR 1 gene a key to successful chemotherapy?]. | 2006 Jun |
1 |
| 39 |
15125696 | Fexofenadine does not affect omeprazole pharmacokinetics: both are putative P-glycoprotein substrates. | 2004 May |
3 |
| 40 |
15217301 | The MDR1 (ABCB1) gene polymorphism and its clinical implications. | 2004 |
1 |
| 41 |
15312146 | Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. | 2004 Aug |
2 |
| 42 |
15359574 | Transport characteristics of fexofenadine in the Caco-2 cell model. | 2004 Aug |
3 |
| 43 |
15536457 | A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. | 2004 Nov |
3 |
| 44 |
14586383 | Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. | 2003 Nov |
1 |
| 45 |
11994059 | MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. | 2002 May |
2 |
| 46 |
12087344 | Effect of St John's wort on the pharmacokinetics of fexofenadine. | 2002 Jun |
1 |
| 47 |
11503014 | Identification of functionally variant MDR1 alleles among European Americans and African Americans. | 2001 Aug |
3 |
| 48 |
10421612 | OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. | 1999 Aug |
2 |